A Randomized Phase III Trial of Concurrent Chemoradiotherapy Followed by Durvalumab Consolidation, With or Without Induction Chemo-Immunotherapy, in Patients With Unresectable Locally Advanced Non-Small Cell Lung Cancer: JCOG2510 (PRIME-CRT).
Kota Kawabata, Ken Masuda, Keita Miura, Yu Saida, Ryo Ko, Hiroaki Akamatsu, Hidehito Horinouchi, Takahito Chiba, Kae Okuma, Hideyuki Harada, Yoshimasa Shiraishi, Yasushi Goto, Shogo Nomura, Noriko Mitome, Haruhiko Fukuda, Isamu Okamoto, Hirotsugu Kenmotsu, Lung Cancer Study Group of the Japan Clinical Oncology Group
Clin Lung Cancer 27(9) 39-43
摘要
摘要
BACKGROUND: Definitive concurrent chemoradiotherapy (cCRT) followed by durvalumab consolidation is the current standard of care for unresectable locally advanced non-small-cell lung cancer (LA-NSCLC). However, survival outcomes in this setting remain unsatisfactory. Although the PACIFIC trial improved outcomes, further intensification of systemic therapy may be required to improve long-term survival. Preclinical and perioperative clinical evidence suggests that introducing immunotherapy in the presence of an intact primary tumor may enhance antitumor immune responses. Recently, early-phase studies have reported the feasibility and potential efficacy of induction chemo-immunotherapy followed by cCRT; however, its clinical benefit has not been confirmed in a phase III trial. PATIENTS AND METHODS: This multicenter, randomized, phase III trial is designed to determine whether the addition of induction chemo-immunotherapy to the current standard strategy of cCRT followed by durvalumab consolidation improves survival outcomes in patients with unresectable LA-NSCLC. Previously untreated patients with unresectable LA-NSCLC without activating EGFR mutations are randomized 1:1 to receive either cCRT followed by durvalumab consolidation or induction chemo-immunotherapy followed by cCRT and durvalumab consolidation. Randomization is adjusted for age, clinical stage, programmed death-ligand 1 expression, and institution. The primary endpoints are progression-free and overall survival. Secondary endpoints include objective response rate, proportion of patients proceeding to cCRT after induction therapy, and adverse events. A total of 212 patients will be enrolled from 60 institutions over 5 years. CONCLUSION: The results of this trial should clarify whether the addition of induction chemo-immunotherapy can enhance curative potential and lead to improved overall survival in patients with unresectable LA-NSCLC.
KM 提取结果
0 个 Figure · 0 个 KM 面板